Azenta Stock (NASDAQ:AZTA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$44.51

52W Range

$40.24 - $69.16

50D Avg

$45.78

200D Avg

$53.60

Market Cap

$2.09B

Avg Vol (3M)

$571.83K

Beta

1.48

Div Yield

-

AZTA Company Profile


Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3,300

IPO Date

Feb 02, 1995

Website

AZTA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 22Sep 21Sep 20
Service$374.55M$323.40M-
Product$180.95M$573.88M-
Products-$181.04M-
Services-$332.67M-

Fiscal year ends in Sep 23 | Currency in USD

AZTA Financial Summary


Sep 23Sep 22Sep 21
Revenue$665.07M$555.50M$513.70M
Operating Income$-73.13M$-4.00M$-46.55M
Net Income$-14.26M$-11.29M$-28.87M
EBITDA$41.18M$49.70M$18.79M
Basic EPS$-0.22$-0.15$-0.39
Diluted EPS$-0.22$-0.15$-0.39

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Nov 12, 24 | 10:09 PM
Q3 24Aug 06, 24 | 7:40 PM
Q2 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
MMSIMerit Medical Systems, Inc.
COOThe Cooper Companies, Inc.
BDXBecton, Dickinson and Company
ATRCAtriCure, Inc.
AKYAAkoya Biosciences, Inc.
HOLXHologic, Inc.
ATRIAtrion Corporation
BLCOBausch + Lomb Corporation
NVSTEnvista Holdings Corporation
ANGOAngioDynamics, Inc.
HAEHaemonetics Corporation
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.